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Apolipoprotein C1 (ApoC1) has a variety of roles in lipid metabolism and transport. It is involved in maintaining and stabilizing high-density lipoprotein (HDL) structure \[[@CR1]\], lipase enzyme regulation \[[@CR1]--[@CR3]\], and inhibition of very low-density lipoprotein (VLDL) binding to both the low-density lipoprotein (LDL) receptor and the LDL receptor-related protein \[[@CR4], [@CR5]\]. It also inhibits cholesterol ester transferase, which shuttles cholesterol esters and triglycerides between lipoproteins \[[@CR6]\]. The overall effects of ApoC1 activity are complex and poorly understood. Overexpression of human ApoC1 in mice produces hyperlipidemia \[[@CR2], [@CR7]\], suggesting that it increases serum lipid levels. However, in the same mouse models, overexpression also protects against diabetes and obesity. In humans, polymorphisms in the ApoC1 promoter have been linked to decreased ApoC1 expression as well as a hereditary hyperlipidemia syndrome (familial dysbetalipoproteinemia), cardiovascular disease, and Alzheimer's disease \[[@CR8]--[@CR12]\].

ApoC1 exists in vivo as a full-length as well as in a truncated (ApoC1′) isoform, lacking the two N-terminal amino acids, threonine and proline. While the ratio of full-length to truncated protein (ApoC1/ApoC1′) has been shown to differ between individuals, it remains highly stable within a given individual over time \[[@CR13]\]. The function of full-length versus truncated protein as well as the significance of the ratio between the two has yet to be elucidated \[[@CR14]\]. However, biophysical analysis revealed maximum flexibility and availability of the amino terminus, making this site a candidate for protein--protein interactions \[[@CR15]\].

The first-known structural polymorphism of ApoC1 was recently identified \[[@CR16]\]. The polymorphism, a threonine to serine substitution at position 45 (T45S) found only in individuals with American Indian or Mexican ancestry, resulted in increased levels of truncated protein and decreased levels of total ApoC1. The initial study found that the mutation was associated with increased distribution to VLDL and a higher body mass index (BMI). A later study of the Oji-Cree community in Canada found that the presence of the polymorphism was associated with decreased plasma leptin and decreased body fat \[[@CR17]\]. While both reports showed a physiological effect, they appeared contradictory. However, the two studies were of dissimilar subjects, with average age and BMI of 44 ± 10 years and 29 ± 6 kg/m \[[@CR18]\] vs. 25 ± 12 years and 25 ± 5 kg/m \[[@CR17]\]. The polymorphism of the promotor region is associated with decreased plasma ApoC1 \[[@CR11]\] and with increased Alzheimer's disease \[[@CR19]\].

The enzyme responsible for cleavage of full-length ApoC1 to its truncated isoform has not been definitively identified, but has been suggested to be dipeptidyl peptidase-4 (DPP-4), a widely distributed serine protease with many known substrates, including cytokines, chemokines, growth factors, and neuropeptides \[[@CR20]\]. While this enzyme prefers cleavage of amino terminal NH~2~-X-Pro with optimum cleavage of NH~2~-Ala-Pro \[[@CR14]\] it also cleaves a large number of other sequences \[[@CR21], [@CR22]\] in an apparent protein-dependent manner. Human ApoC1 contains NH~2~-Thr-Pro, a suitable substrate for DPP-4 \[[@CR21]\]. In vitro assays have shown that DPP-4 is capable of cleaving both the wild-type (T45) and variant (S45) ApoC1, but that S45 ApoC1 is cleaved more readily, which is consistent with the higher proportion of cleaved protein found in individuals with the polymorphism \[[@CR16]\].

Among the many known DPP-4 substrates is the gastrointestinal hormone, glucagon-like peptide-1 (GLP-1). GLP-1 acts to increase insulin secretion, decrease glucagon production, and slow gastric emptying following meals, but becomes inactivated by cleavage with DPP-4 \[[@CR20], [@CR23]\]. For this reason, DPP-4 has become a target for management of type 2 diabetes. The drug sitagliptin phosphate is an FDA-approved DPP-4 inhibitor shown to lower mean blood glucose levels in diabetics by augmenting GLP-1 levels \[[@CR24]\]. Given the extensive correlation of ApoC1 to disease and the unexplained presence of two isoforms of the protein, it is of interest to determine the effect of sitagliptin on ApoC1 truncation.

This study reports the results of healthy non-diabetics who were treated with sitagliptin to compare ApoC1/ApoC1′ ratios before and after treatment. A significant decrease in truncation followed treatment, thus providing evidence that DPP-4 is responsible for cleavage of ApoC1 in humans in vivo.

Methods {#Sec2}
=======

Five healthy volunteers (2F/3 M, age 31.2 + 8.6, BMI 23.2 + 3.1) received 3-day administration of sitagliptin (100 mg/day). Blood was drawn into citrate anticoagulant at baseline and 3 days. Mouse and dog plasmas were purchased from Innovative Research, Novi, MI, USA. The ratio of full-length to truncated ApoC1 was determined by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry as described elsewhere \[[@CR25]\] before and after drug administration. Plasma ApoC1 concentrations were determined with a commercial ELISA kit (Abcam, Cambridge, MA). Data were analyzed using Prism v5.0c (GraphPad Software, La Jolla, CA). Statistical analyses were performed using the Wilcoxon matched pairs signed pairs test.

This study was approved by the Institutional Review Board of the University of Minnesota. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation at the University of Minnesota and with the Helsinki Declaration of 1975, as revised in 2013. Informed consent was obtained from all patients for being included in the study.

Results {#Sec3}
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The method used in this study has at least two unique properties. First is that carefully controlled reverse phase extraction of diluted plasma with analysis by MALDI-TOF mass spectrometry results in a small number of intense peaks. The second is that the ratios of protein isoforms found the spectrum are extremely reproducible. The ratio of full-length to truncated ApoC1 is an example (Fig. [1](#Fig1){ref-type="fig"}). The mass difference in these peaks (*m*/*z* = 6632 − 6434 = 198 amu) corresponds to loss of Thr-Pro, the expected cleavage of the amino terminal dipeptide. There are no other known modifications that are consistent with this mass change. This isoform ratio was measured before and after sitagliptin administration (Fig. [1](#Fig1){ref-type="fig"}). An average 2.5 ± 0.28-fold increase in this ratio was observed (before average = 2.05 + 0.22, range 1.76--2.2; after average = 5.1 + 0.9, range 3.96--6.25), corresponding to an average 50% decline of the truncated ApoC1 (33% to 17%). Prior studies of plasma drawn from healthy individuals at baseline and again at 3 years showed stable ratios of full-length to truncated ApoC1 with an average of 0.96 ± 0.07 (ratio at 3 year/ratio at baseline \[[@CR25]\]). Thus, the change observed following sitagliptin was exceptional, corresponding to 35 standard deviations greater than normal variation. This also occurred in only 3 days.Fig. 1Effect of sitagliptin treatment on isoforms of ApoC1. MALDI-TOF profile of ApoC1 from subject 1 prior to (**a**) and after (**b**) treatment with sitagliptin. The peak at *m/z* = 6632 corresponds to full-length ApoC1 while the peak at 6434 is truncated ApoC1. *ApoC1* Apolipoprotein C1, *MALDI*-*TOF* matrix-assisted laser desorption ionization-time of flight

Although truncation may serve several purposes, one may be protein turnover. For example, lower ApoC1 in persons with the T45S variant would be consistent with enhanced removal of the truncated protein from the circulation. If correct, inhibition of truncation due to sitagliptin should result in decreased turnover and a corresponding increase of total ApoC1. However, plasma ApoC1 concentrations were unchanged after sitaglipin administration as determined with a commercial ELISA kit (Abcam, Cambridge, MA) (average ratio for each individual before/after drug = 0.99 + 0.05, range among subjects = 36--53 µg ApoC1/mL).

Additional evidence for ApoC1 cleavage by DPP-4 was obtained by species comparisons. Mouse ApoC1 contains the putative optimum DPP-4 substrate sequence of NH~2~-Ala-Pro. Earlier studies by electrospray ionization mass spectrometry reported a preponderance of truncated ApoC1 in the mouse \[[@CR26]\]. MALDI-TOF profile analysis by the method used for human ApoC1 confirmed this finding with a major peak at *m/z* = 6825, corresponding to truncated mouse ApoC1 and only trace levels of a component corresponding to the full-length form at *m/z* = 6994 (Fig. [2](#Fig2){ref-type="fig"}a). In contrast, canine ApoC1 contains the amino terminal sequence of NH~2~-Ala-Gly, a poorer substrate for DPP-4 \[[@CR21]\]. Earlier studies by electrospray mass spectrometry reported a single isoform of canine ApoC1 at *m/z* = 7042 \[[@CR27]\], corresponding to the full-length protein. In agreement, MALDI-TOF mass spectrometry by the method outlined in this study showed a single peak at the *m/z* corresponding to full-length canine ApoC1 (Fig. [2](#Fig2){ref-type="fig"}b).Fig. 2ApoC1 and ApoC1′ peak intensities in mouse and dog plasmas. **a** MALDI-TOF profile showing an expanded view of the ApoC1 region from a representative mouse plasma sample. **b** MALDI-TOF profile showing an expanded view of the ApoC1 region from a representative dog plasma sample. *ApoC1* Apolipoprotein C1, *ApoC1′* truncated isoform of Apolipoprotein C1, *MALDI*-*TOF* matrix-assisted laser desorption ionization-time of flight
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Overall, this study supported the conclusion that truncation of ApoC1 arises from the action of DPP-4, as hypothesized. This was indicated by a dramatic decline of truncated ApoC1 following sitagliptin administration in each of the five subjects. Extensive prior studies found no basis for this large change among the healthy population \[[@CR25]\]. This interpretation was based on an assumed specificity of sitagliptin for DPP-4. Thus, a more precise conclusion was that sitagliptin inhibited truncation of ApoC1. Consequently, change in the ratio of ApoC1 isoforms is an unappreciated side effect of DPP-4 inhibitors.

The decline of truncated protein was consistent with the target level for DPP-4 inhibition by sitagliptin. Given a mean residence time for ApoC1 of 3.7 + 0.3 days \[[@CR28]\], or a half-life of 2.56 days, full inhibition of DPP-4 should result in a 50% decline of truncated protein in approximately 2.56 days. Assuming first-order kinetics with respect to ApoC1 and DPP-4, fifty percent decline in 3.0 days corresponded to approximately 85% inhibition of DPP-4, very nearly the target for drug administration \[[@CR29]\].

Although the role of truncation is not known, several suggestions indicate that further study is warranted. It is also possible that measuring the truncation level of ApoC1 could be used to monitor drug efficacy in individual patients, similar to how glycation of hemoglobin (hemoglobin A1c) is used to monitor blood glucose levels over time in diabetic patients.

Conclusion {#Sec5}
==========

In this study we sought to determine if oral administration of sitagliptin altered the proportion of ApoC1 isoforms circulating in humans. Results indicated a dramatic change in ApoC1 truncation, consistent with a high level of DPP-4 inhibition by sitagliptin.
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